A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Opus Genetics plans to submit an application to the FDA.Sub-event
The partnership aims to advance gene therapy development and seeks IND filing with the FDA.1 source
Keep exploring
The entities involved
Related events
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- FDA placed a clinical hold on a gene therapy involving Hunter.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
Coverage
Newest first; wire copies grouped- GlobeNewswireOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH1